Initial Findings from a High Genetic Risk Prostate Cancer Clinic
| Autor: | Alison M. Mondul, Mallory Luke, Samuel D. Kaffenberger, Leander Van Neste, Bumsoo Park, Elena M. Stoffel, Simpa S. Salami, Michael Sessine, Michelle F. Jacobs, Amy Kasputis, Todd M. Morgan, Kara J. Milliron, Marissa Solorzano, Sofia D. Merajver, Deborah R. Kaye, Erin F. Cobain, Laura Caba, Randy Vince, Tudor Borza, Sanjay Das |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Biopsy Urology Urinalysis Germline Prostate cancer Risk Factors Internal medicine medicine Humans Genetic Predisposition to Disease Genetic Testing Genetic risk Medical History Taking Life Style CHEK2 Early Detection of Cancer Germ-Line Mutation Aged Digital Rectal Examination Genetic testing BRCA2 Protein medicine.diagnostic_test BRCA1 Protein business.industry Prostate Prostatic Neoplasms Middle Aged Prostate-Specific Antigen Nutrition Surveys medicine.disease Colorectal Neoplasms Hereditary Nonpolyposis Lynch syndrome Checkpoint Kinase 2 Prostate cancer screening business |
| Zdroj: | Urology. 156:96-103 |
| ISSN: | 0090-4295 |
| Popis: | Objective To improve prostate cancer screening for high-risk men, we developed an early detection clinic for patients at high genetic risk of developing prostate cancer. Despite the rapidly growing understanding of germline variants in driving aggressive prostate cancer and the increased availability of genetic testing, there is little evidence surrounding how best to screen these men. Methods We are reporting on the first 45 patients enrolled, men between the ages of 35–75, primarily with known pathogenic germline variants in prostate cancer susceptibility genes. Screening consists of an intake lifestyle survey, PSA, DRE, and SelectMDx urine assay. A biopsy was recommended for any of the following indications: 1) abnormal DRE, 2) PSA above threshold, or 3) SelectMDx above threshold. The primary outcomes were number needed to screen, and number needed to biopsy to diagnose a patient with prostate cancer. Results Patients enrolled in the clinic included those with BRCA1 (n=7), BRCA2 (n=16), Lynch Syndrome (n=6), and CHEK2 (n = 4) known pathogenic germline variants. The median age and PSA were 58 (range 35–71) and 1.4 ng/ml (range 0.1–11.4 ng/ml), respectively. 12 patients underwent a prostate needle biopsy and there were 4positive biopsies for prostate cancer. Conclusion These early data support the feasibility of opening a dedicated clinic for men at high genetic risk of prostate cancer. This early report on the initial enrollment of our long-term study will help optimize early detection protocols and provide evidence for personalized prostate cancer screening in men with key pathogenic germline variants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect